Korro Bio Inc. (KRRO)
33.16
-2.95 (-8.17%)
At close: Jan 29, 2025, 3:59 PM
33.09
-0.21%
After-hours Jan 29, 2025, 04:00 PM EST
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases.
Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio Inc.
| Country | United States |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Ram Aiyar MBA, Ph.D. |
Contact Details
Address: One Kendall Square Cambridge, Massachusetts United States | |
| Website | https://www.korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President & Director |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Vineet Agarwal M.B.A. | Chief Financial Officer |
| Andrew Fraley Ph.D. | Co-Founder & Advisor |
| Dr. Jean-Francois Formela M.D., MBA | Co-Founder & Independent Director |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder & Advisor |
| Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President & General Counsel |
| Marco A. Passini Ph.D. | Vice President & Head of CNS biology |
| Nessan Bermingham Ph.D. | Co-Founder & Independent Chairman of the Board |
| Stephanie Engels | Senior Vice President and Head of People & Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 10, 2024 | 424B3 | Filing |
| Dec 10, 2024 | 424B3 | Filing |
| Dec 06, 2024 | 424B5 | Filing |
| Dec 02, 2024 | POS AM | Filing |
| Dec 02, 2024 | POS AM | Filing |
| Dec 02, 2024 | S-3 | Filing |
| Nov 21, 2024 | 424B3 | Filing |
| Nov 21, 2024 | 424B3 | Filing |
| Nov 21, 2024 | 8-K | Current Report |